U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia
-
- Firoozeh Alvandi
- Office of Hematology and Oncology Products, Office of New Drugs, Maryland, USA
-
- Virginia E. Kwitkowski
- Office of Hematology and Oncology Products, Office of New Drugs, Maryland, USA
-
- Chia-Wen Ko
- Office of Biostatistics, Maryland, USA
-
- Mark D. Rothmann
- Office of Biostatistics, Maryland, USA
-
- Stacey Ricci
- Office of Hematology and Oncology Products, Office of New Drugs, Maryland, USA
-
- Haleh Saber
- Office of Hematology and Oncology Products, Office of New Drugs, Maryland, USA
-
- Debasis Ghosh
- Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
-
- Janice Brown
- Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
-
- Erika Pfeiler
- Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
-
- Elsbeth Chikhale
- Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
-
- Joseph Grillo
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
-
- Julie Bullock
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
-
- Robert Kane
- Office of Hematology and Oncology Products, Office of New Drugs, Maryland, USA
-
- Edvardas Kaminskas
- Office of Hematology and Oncology Products, Office of New Drugs, Maryland, USA
-
- Ann T. Farrell
- Office of Hematology and Oncology Products, Office of New Drugs, Maryland, USA
-
- Richard Pazdur
- Office of Hematology and Oncology Products, Office of New Drugs, Maryland, USA
説明
<jats:title>Abstract</jats:title> <jats:p>On October 26, 2012, the U.S. Food and Drug Administration (FDA) granted accelerated approval to omacetaxine mepesuccinate (Synribo; Teva Pharmaceuticals USA, Inc., North Wales, PA, http://www.tevausa.com) for the treatment of adult patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). The approval was based on the FDA review of data from 111 patients with CML in CP or in AP who had received two or more prior TKIs, including imatinib. Major cytogenetic response was achieved in 18% of patients with CP, with a median response duration of 12.5 months. Major hematologic response was achieved in 14% of patients with AP, with a median response duration of 4.7 months. The FDA safety evaluation was based on submitted data from 163 patients with CP or AP CML who had received at least one dose of omacetaxine mepesuccinate. The safety evaluation was limited by the single-arm design of the clinical trials as conducted in a small number of previously treated patients. The most common (≥20%) adverse reactions of any grade in enrolled patients included thrombocytopenia, anemia, neutropenia, diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, and infection. The FDA concluded that omacetaxine mepesuccinate has shown activity and a favorable benefit-to-risk profile for the studied population of adult patients with CML (CP or AP) with resistance and/or intolerance to two or more TKIs. Further evidence of response durability to verify clinical benefit is pending.</jats:p>
収録刊行物
-
- The Oncologist
-
The Oncologist 19 (1), 94-99, 2013-12-05
Oxford University Press (OUP)
